Preclinical SPECT

Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of eight posters at the upcoming AACR Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of eight posters at the upcoming AACR Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023.
  • The Company will also host a virtual investor event on Tuesday, April 18 at 6:30 PM ET.
  • A webcast of the event will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations .
  • The archived webcast will be available on the Company’s website within 24 hours after the event and will be available for 30 days following the event.

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG

Retrieved on: 
Wednesday, December 1, 2021

GSK4381562 is a fully human IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells.

Key Points: 
  • GSK4381562 is a fully human IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells.
  • GSK4381562 is a fully human, IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells.
  • In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562; preclinical).
  • In addition, any forward-looking statements contained in this press release are based on assumptions that Surface Oncology believes to be reasonable as of this date.

Nuclear Imaging Equipment Market by Product, Application & End-user - Global Forecasts to 2025

Retrieved on: 
Monday, March 15, 2021

The global nuclear imaging equipment market is projected to reach USD 4,604.9 million by 2025 from an estimated USD 3,803.5 million in 2020, at a CAGR of 3.9% during the forecast period.

Key Points: 
  • The global nuclear imaging equipment market is projected to reach USD 4,604.9 million by 2025 from an estimated USD 3,803.5 million in 2020, at a CAGR of 3.9% during the forecast period.
  • Based on product, the nuclear imaging equipment market is segmented into hybrid PET imaging systems, SPECT imaging systems, and planar scintigraphy imaging systems.
  • Based on application, the nuclear imaging equipment market is segmented into oncology, cardiology, neurology, and other applications.
  • Based on end user, the nuclear imaging equipment market is segmented into hospitals, imaging centers, academic & research centers, and other end users.

Nuclear Medicine/Radiopharmaceuticals Market Worth $5.2 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, January 27, 2020

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine.

Key Points: 
  • Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine.
  • The diagnostic nuclear medicine segment is further categorized into SPECT and PET radiopharmaceuticals.
  • The SPECT radiopharmaceuticals segment is expected to account for the largest share of the market in 2019.
  • Based on procedural volume assessment, the Nuclear Medicine Market is segmented into diagnostic and therapeutic procedures.

Nuclear Medicine/Radiopharmaceuticals Market Worth $5.2 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, January 27, 2020

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine.

Key Points: 
  • Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine.
  • The diagnostic nuclear medicine segment is further categorized into SPECT and PET radiopharmaceuticals.
  • The SPECT radiopharmaceuticals segment is expected to account for the largest share of the market in 2019.
  • Based on procedural volume assessment, the Nuclear Medicine Market is segmented into diagnostic and therapeutic procedures.

Huntsman Cancer Institute Becomes the First US Installation of the nanoScan 3 Tesla PET/MRI

Retrieved on: 
Tuesday, October 2, 2018

says Jeffrey Yap PhD, Co-Director, Center for Quantitative Cancer Imaging, Huntsman Cancer Institute.

Key Points: 
  • says Jeffrey Yap PhD, Co-Director, Center for Quantitative Cancer Imaging, Huntsman Cancer Institute.
  • "We are delighted to further expand the research capabilities of HCI enabling the use of quantitative multimodality imaging."
  • "The nanoScan PET/MRI 3T is the only integrated whole-body PET/MRI on the market that provides users with both high-end PET and 3T MRI.
  • Its nanoScan product family is the first-line choice for preclinical imaging including the world's first integrated preclinical PET/MRI, PET/CT, SPECT/CT and SPECT/MRI combinations.

Bruker Introduces New High Performance Preclinical PET/CT Si78 System

Retrieved on: 
Friday, September 14, 2018

SEATTLE, Sept. 14, 2018 /PRNewswire/ --Bruker today announced the introduction of the new preclinical PET/CT Si78 scanner for whole-body molecular imaging at the World Molecular Imaging Congress ( www.wmis.org/2018-wmic ).

Key Points: 
  • SEATTLE, Sept. 14, 2018 /PRNewswire/ --Bruker today announced the introduction of the new preclinical PET/CT Si78 scanner for whole-body molecular imaging at the World Molecular Imaging Congress ( www.wmis.org/2018-wmic ).
  • The PET/CT Si78 is addressing the latest needs of preclinical imaging scientists by combining homogeneous sub-millimeter PET spatial resolution over a large field of view (FoV) with minimal X-ray radiation dose.
  • The PET/CT Si78 has already demonstrated excellent results in oncology, neurology, cardiovascular, lung and bone imaging."
  • Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.